Home
/
Arcturus Therapeutics Holdings Inc.
/
Financials
/
Quarterly
Arcturus Therapeutics Holdings Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Arcturus Therapeutics Holdings Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$17.15M
Nov 12, 2025
Q2
2025
Jun 30, 2025
$28.30M
Aug 11, 2025
Q1
2025
Mar 31, 2025
$29.38M
May 12, 2025
Q3
2025
Sep 30, 2024
$41.67M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$49.86M
Aug 11, 2025
Q1
2025
Mar 31, 2024
$38.01M
May 12, 2025
Q3
2024
Sep 30, 2023
$45.14M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$10.52M
Aug 5, 2024
Q1
2024
Mar 31, 2023
$80.29M
May 8, 2024
Q3
2023
Sep 30, 2022
$13.37M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$27.09M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$5.24M
May 9, 2023
Q3
2022
Sep 30, 2021
$2.44M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$2.00M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$2.13M
May 9, 2022
Q3
2021
Sep 30, 2020
$2.33M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$2.32M
Aug 10, 2021
Q1
2021
Mar 31, 2020
$2.65M
May 10, 2021
Q3
2020
Sep 30, 2019
$3.32M
Nov 9, 2020
Q2
2020
Jun 30, 2019
$10.15M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($13.45M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($9.18M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($9.18M)
Aug 11, 2025
Q3
2025
Mar 31, 2025
($14.08M)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($14.08M)
May 12, 2025
Q3
2025
Sep 30, 2024
($6.90M)
Nov 12, 2025
Q3
2025
Jun 30, 2024
($17.22M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($17.22M)
Aug 11, 2025
Q2
2025
Mar 31, 2024
($26.82M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($26.82M)
May 12, 2025
Q3
2025
Mar 31, 2024
($26.82M)
Nov 12, 2025
Q3
2024
Sep 30, 2023
($16.22M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($52.55M)
Aug 5, 2024
Q3
2024
Jun 30, 2023
($52.55M)
Nov 7, 2024
Q2
2024
Mar 31, 2023
$50.75M
Aug 5, 2024
Q3
2024
Mar 31, 2023
$50.75M
Nov 7, 2024
Q1
2024
Mar 31, 2023
$50.75M
May 8, 2024
Q3
2023
Sep 30, 2022
($35.27M)
Nov 14, 2023
Q3
2023
Jun 30, 2022
($21.56M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($21.56M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($16.51M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($11.62M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($16.83M)
May 12, 2025
Q3
2025
Sep 30, 2024
($10.74M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($21.13M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($30.41M)
May 12, 2025
Q3
2024
Sep 30, 2023
($19.31M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($55.37M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
$14.76M
May 8, 2024
Q3
2023
Sep 30, 2022
($36.81M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($22.09M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($50.38M)
May 9, 2023
Q3
2022
Sep 30, 2021
($53.82M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($53.72M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($57.67M)
May 9, 2022
Q3
2021
Sep 30, 2020
($20.94M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($10.04M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($9.46M)
May 10, 2021
Q3
2020
Sep 30, 2019
($7.62M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($572.0K)
Aug 10, 2020